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inTRODUCTiOn
One cause of early graft failure following coronary and peripheral vein grafting is kinking or mechani-
cal twisting of the conduit. The blind tunneling necessitated in peripheral bypasses can lead to this 
consequence (1). In coronary artery bypass grafting (CABG), grafts to the posterior branches of the 
right or circumflex coronary arteries are placed to the back of the heart and are generally the longest 
aortocoronary grafts. These grafts are particularly prone to twisting and kinking. Additionally, single 
vein grafts to two or more coronary branches (“sequential vein grafts”) present special challenges 
with respect to maintenance of proper alignment (2, 3). The coronary vein graft failure rate at 1 year 
in the PRoject of Ex vivo Vein graft ENgineering via Transfection IV (PREVENT IV) cohort was 
25%, suggesting that early graft failure is a significant problem (4, 5). The incidence of vein graft 
failure due to twisting or kinking is not well studied, though some reports estimate that obstructing 
lesions, including but not limited to twisting or kinking, account for 15–25% of early (<1 year) graft 
failures (6–8).
Preparation and preservation techniques have advanced the field of solid organ allotransplanta-
tion, but vein graft failure rates suggest room for improvement in the handling of saphenous vein 
(SV) harvested for autotransplantation. Interventions for ex vivo graft treatment, including appropri-
ate choice of preservation solution and minimization of manual pressure distension via chemical 
vasodilators such as papaverine, have been proposed (9–12). Additionally, the “no-touch” technique 
has emerged as a method of minimizing detrimental handling of graft during harvest with adventitial 
preservation (4, 13–15).
Marking of the SV graft using a surgical skin marker in an “off-label” fashion represents another 
such preparation technique and is the most commonly employed method of preventing graft tor-
sion (16). This marking allows for the maintenance of continuous alignment along the length of 
the vein in the same longitudinal plane. These lines provide a visible guide for surgeons to use 
during conduit routing and tunneling to avoid mechanical obstructions related to vein alignment 
(17). While operating rooms have adapted less traumatic methods of vein harvest, preservation, 
and distension, surgical skin marker use remains ubiquitous as the primary method to maintain 
graft orientation. The use of surgical skin markers during graft preparation is toxic to the tissue and 
impairs physiologic function (16). We argue that the data support avoidance of standard surgical 
skin markers for marking on vascular tissue; We further contend that brilliant blue FCF (for coloring 
food) may represent a viable alternative dye for intraoperative graft marking.
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CURREnT STATUS OF GRAFT MARKinG
Also known as crystal violet, gentian violet has emerged as the 
most common dye used in surgical skin marking in the United 
States, replacing methylene blue in the mid-1990s (18). Most com-
mercially available markers approved for use to mark skin contain 
10% gentian violet dye in an isopropyl alcohol solvent, at up to 
50% by weight (16). In addition to off-label use on vein grafts, 
gentian violet-based surgical skin markers are routinely used to 
mark other human tissue intraoperatively, including tendon and 
eye tissue such as donor cornea and anterior lens capsule (19–22). 
Influence of the gentian violet marker on residual human ham-
string tendon following graft placement during anterior cruciate 
ligament reconstruction was assessed using an in vitro live–dead 
assay. The study found that marking caused pronounced cell death 
and inhibited tenocyte migration, representing a total failure of 
explant vigor (20). While the effect on clinical outcome has not 
yet been realized, the authors recommended minimization of 
tendon marking. In ocular tissue, gentian violet pen markings 
are often made on a microscale on transplanted corneal tissue 
to maintain orientation and to anterior lens capsular tissue to 
facilitate intraoperative visualization in cataract surgery (19, 22). 
To this effect, there is evidence that suggests the dye may be toxic 
to donor corneal endothelium in Descemet-stripping automated 
endothelial keratoplasty and to anterior lens epithelial cells in 
corneal surgery.
Few studies have addressed the mechanism by which gentian 
violet affects mammalian cells, at the molecular level. On the 
one hand, gentian violet blocks the activity of nicotinamide 
adenine dinucleotide phosphate oxidases, avoiding the genera-
tion of superoxide radicals and subsequent inflammation (23). 
However, gentian violet also has been shown to bind to intracel-
lular deoxyribonucleic acid, precluding DNA replication and 
excision repair (24).
The effect of gentian violet on human vessels is controversial. 
It was previously reported that when applied to human venous 
tissue, gentian violet acutely preserved physiologic functional 
responses better than methylene blue, as measured on an organ 
bath (16, 18). More specifically, these studies showed that topical 
gentian violet application did not significantly impair smooth 
muscle contractile strength induced by potassium chloride and 
phenylephrine stimuli or vasodilatory response to cholinergics 
and calcium channel blockers; dilatory responses to sodium 
nitroprusside, however, were significantly decreased (18). 
During the course of physiologic studies using human SV surgi-
cal remnants from CABG patients, our laboratory observed that 
tissue segments with signs of surgical skin marker containing 
both gentian violet and isopropyl alcohol displayed markedly 
impaired responses in the muscle bath. Human SV samples 
were marked with the standard surgical skin markers and, after 
equilibration on an organ bath, were challenged with vasoactive 
agents. Compared with unmarked control segments, the marked 
segments demonstrated impaired contractility in response to 
potassium chloride and phenylephrine agonists and decreased 
endothelial-dependent relaxation in response to carbachol, a 
cholinomimetic (16). The cytotoxic effects of topical gentian 
violet dye on cultured human umbilical venous smooth muscle 
cells has recently been reported. Brief exposure of these cells to 
topical gentian violet dye at subclinical concentrations leads to 
cytologic fixation. Additionally, this treatment leads to enhanced 
dead cell protease release relative to control cells, as determined 
via the CytoTox-Glo assay (25).
Isopropyl alcohol is a clear, colorless liquid with many com-
mercial applications, including cosmetics, antifreezes, and clean-
ers. It is the solvent used for gentian violet in current surgical 
skin markers. Topical application of isopropyl alcohol on a vessel 
carries the risk of systemic absorption, although subsequent 
hepatic conversion to acetone via alcohol dehydrogenase may 
reduce the harm. Unlike other alcohols, isopropyl alcohol itself, 
rather than its product of oxidation, is responsible for the toxic 
effects (26, 27).
The physiologic effect of isopropyl alcohol on human SV was 
also investigated in our laboratory and reported in 2011 (16). As 
seen with standard surgical skin marking, contractile responses 
of human SV rings in response to potassium chloride and phe-
nylephrine challenge were decreased in tissues briefly preserved 
in 50% aqueous isopropyl alcohol, when assessed on an organ 
bath (16). Endothelial-dependent relaxation was also impaired 
with isopropyl alcohol-preserved tissues. Diminished contractile 
responses to potassium chloride have been associated with 
decreased viability of human SV. Evidence of isopropyl alcohol-
induced cellular damage has been further supported by staining 
with trypan blue, a vital stain used to detect dead tissue. Cultured 
human umbilical venous smooth muscle cells, after a 15-min 
exposure to 50% isopropyl alcohol, histologically demonstrated 
significantly increased uptake of trypan blue. Additionally, 
isopropyl alcohol exposure, as seen with gentian violet, led to 
an increase in cytotoxicity as determined via the CytoTox-Glo 
assay (25). Most concerning, this pattern of acute cellular injury 
to the conduit may portend a poor graft performance, leading to 
thrombosis and acceleration of neointimal hyperplasia (28–30).
pROpOSED ALTERnATiVE
A common food colorant, FCF is a triarylmethane water-soluble 
dye that is found to be safe in commonly ingested doses (31). 
Topically, FCF appears as a distinct bright blue similar to methylene 
blue and, like current vein graft dyes, is easily distinguishable in 
the intraoperative setting from blood, irrigants, and surrounding 
muscle and connective tissue (Figure 1). As a structural analog 
of brilliant blue G, it was plausible that FCF too may inhibit P2X7 
receptors, cell surface receptors whose activation is induced by 
the trauma of intraoperative graft manipulation. Our laboratory 
has shown that these receptors are implicated in proliferation, 
migration, and apoptosis of vascular smooth muscle cells (32). 
Due to its established safety profile and potential for amelioration 
of preparation-induced conduit injury via P2X7 receptor inhibi-
tion, FCF represented a practical candidate for a substitute vein 
graft dye (25, 32).
Evidence of FCF-governed P2X7 inhibition has been reported, 
primarily from our laboratory. The P2X7 agonist, 2′(3′)-O-(4-
benzoylbenzoyl)adenosine-5′-triphosphate (BzATP), was added 
to an organ bath containing suspended unprepared human SV 
rings left as untreated control or pretreated with a topical FCF. 
FiGURE 1 | ink markings on human saphenous vein graft. Left – unmarked human saphenous vein; Middle – human saphenous vein marked with a standard 
surgical skin marker (gentian violet dye and isopropyl alcohol solvent); Right – human saphenous vein marked with brilliant blue FCF-based marking pen (FCF dye 
and glycerol solvent).
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The FCF-treated rings demonstrated reduced BzATP-induced, 
P2X7-governed contractile responses, suggesting that P2X7 
receptors were inhibited (32). P2X7 receptor activation leads to 
increases in intracellular calcium concentrations (33). Further 
evidence supporting the proposed mechanism of action of FCF 
was recently reported, as FCF pretreatment of rat aorta prevented 
intracellular calcium flux governed by BzATP-induced P2X7 
activation, as detected by a FluoroPlex apparatus (25).
We have also examined the topical effect of FCF on vascular 
conduit. Human SV samples were obtained from CABG patients 
prior to preparation or preservation, and baseline physiologic 
responses were determined in an organ bath (32). The decrement 
in endothelial-dependent relaxation observed after 2 h of preser-
vation in heparinized Plasma-Lyte A was mitigated by the addi-
tion of aqueous FCF to the preservation solution (32). Moreover, 
in some human SV samples that were initially unresponsive 
to a depolarizing KCl stimulus, FCF restored smooth muscle 
contractility and hence, functional viability (32). Exposure of cul-
tured human umbilical venous smooth muscle cells to clinically 
applicable doses of topical FCF has recently been shown to lead 
to neither increased trypan blue staining relative to control nor 
increased dead cell protease release via the CytoTox-Glo assay, 
in contrast to the effects observed with topical gentian violet and 
isopropyl alcohol (25).
In addition to its effects on acute physiologic responses 
and cellular viability of vascular tissue, we have also reported 
the influence of FCF treatment on intimal hyperplasia (32). 
Unmanipulated human SV rings were treated for 2  h in solu-
tion with and without FCF, and maintained in organ culture 
over 14 days. While a significant increase in intimal thickness 
was noted among untreated veins, this was mitigated in the 
FCF-treated vein group (32). FCF, as a topical vein graft treatment 
in a rabbit external jugular–carotid artery interposition model, 
led to reduced neointimal growth relative to control grafts (34). 
Finally, platelet-derived growth factor-induced migration and 
proliferation were examined in A7r5 smooth muscle cells. FCF 
pretreatment abrogated both cellular migration and prolifera-
tion (34).
COnCLUSiOn
The “off-label” use of surgical skin markers have been shown 
to impair physiologic responses in human SV graft and to be 
cytotoxic. Surgeons should consider minimizing or eliminat-
ing the off-label use of surgical skin markers for vein marking. 
FCF is a plausible alternative dye for graft marking in that it 
preserves endothelial and smooth muscle function and inhibits 
neointimal growth in human SV. Moreover, FCF is also the only 
dye that is currently approved by the FDA for use in marking 
human SV.
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